Wall Street analysts forecast that Radius Health, Inc. (NASDAQ:RDUS – Get Rating) will post $0.08 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Radius Health’s earnings. The lowest EPS estimate is ($0.04) and the highest is $0.37. Radius Health reported earnings of ($0.35) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 122.9%. The business is scheduled to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Radius Health will report full-year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.59) to ($0.08). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.23 per share, with EPS estimates ranging from ($0.18) to $0.60. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Radius Health.
Radius Health (NASDAQ:RDUS – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). During the same period in the prior year, the business earned ($0.34) earnings per share.
RDUS traded up $0.02 on Friday, hitting $6.12. 776,632 shares of the company were exchanged, compared to its average volume of 910,875. Radius Health has a 12 month low of $4.97 and a 12 month high of $23.00. The company has a market cap of $291.13 million, a PE ratio of -3.97 and a beta of 1.02. The stock’s fifty day moving average is $7.36 and its 200-day moving average is $8.61.
In other news, major shareholder Target N. V. Biotech bought 477,824 shares of the stock in a transaction dated Wednesday, May 18th. The shares were bought at an average price of $5.57 per share, for a total transaction of $2,661,479.68. Following the completion of the purchase, the insider now owns 8,733,538 shares in the company, valued at $48,645,806.66. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.73% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC grew its position in Radius Health by 1.8% during the third quarter. Voya Investment Management LLC now owns 32,716 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 577 shares in the last quarter. Royal Bank of Canada grew its position in Radius Health by 16.8% during the third quarter. Royal Bank of Canada now owns 5,956 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 855 shares in the last quarter. Deutsche Bank AG grew its position in Radius Health by 0.5% during the fourth quarter. Deutsche Bank AG now owns 282,291 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 1,419 shares in the last quarter. California State Teachers Retirement System grew its position in Radius Health by 2.7% during the fourth quarter. California State Teachers Retirement System now owns 59,581 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 1,555 shares in the last quarter. Finally, E Fund Management Co. Ltd. grew its position in Radius Health by 18.4% during the first quarter. E Fund Management Co. Ltd. now owns 12,738 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,981 shares in the last quarter.
About Radius Health (Get Rating)
Radius Health, Inc, a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.
- Get a free copy of the StockNews.com research report on Radius Health (RDUS)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.